Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor

NCT05009966 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Gastric Cancer (GC)
Gastroesophageal Junction (GEJ) Cancer
Pancreatic Cancer

Interventions

DRUG: SYSA1801 for injection

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.